<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-4157</journal-id>
<journal-title><![CDATA[Biomédica]]></journal-title>
<abbrev-journal-title><![CDATA[Biomédica]]></abbrev-journal-title>
<issn>0120-4157</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-41572018000400527</article-id>
<article-id pub-id-type="doi">10.7705/biomedica.v38i4.388</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Profile of antiretroviral agents use in Colombia]]></article-title>
<article-title xml:lang="es"><![CDATA[Perfil de utilización de antirretrovirales en Colombia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[Jorge E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Atehortúa-Otero]]></surname>
<given-names><![CDATA[Miguel A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cortés-Mejía]]></surname>
<given-names><![CDATA[Diego A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Tecnológica de Pereira Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>38</volume>
<numero>4</numero>
<fpage>527</fpage>
<lpage>533</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-41572018000400527&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-41572018000400527&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-41572018000400527&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Since the beginning of the epidemic, human immunodeficiency virus (HIV) has taken more than 36 million lives.  Objective: To determine the antiretroviral drug prescription patterns in a population of individuals with HIV infection in Colombia.  Materials and methods: Cross-sectional study analyzing the profiles of patients treated with antiretroviral drugs between April 1st and September 30th, 2015. The sociodemographic, pharmacological, and comorbidity variables were identified. Individuals with a positive diagnosis of HIV of all ages and both genders were included.  Results: We found 641 patients with a mean age of 39.0±17 years who were predominantly male (60.2%). The most used medications were lamivudine-zidovudine (51.6%), lopinavir-ritonavir (36%) and efavirenz (24.5%). The combination of lamivudine-zidovudine plus lopinavir-ritonavir was the most prescribed regimen (29.5%), but a total of 80 different regimens was identified. Being an adult between the ages of 45-64 years (OR=2.25; 95%CI 1.367-3.713) was associated with a greater probability of receiving 4 or more antiretrovirals. A total of 267 (41.6%) patients used at least one comedication (range: 1-18 drugs), especially anti-ulcer (57.3%), lipid-lowering (28.8%) and anti-hypertensive (28.5%) drugs.  Conclusions: Patients undergoing antiretroviral treatment are receiving medications with elevated intrinsic values at the recommended doses and present comorbidities associated with chronic agerelated conditions. However, these patients receive a great variety of regimens that are not included in the clinical practice guidelines.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción. La infección por HIV es una pandemia que actualmente se controla con el tratamiento farmacológico, el cual, además, prolonga la expectativa de vida del paciente.  Objetivo. Determinar los patrones de prescripción de fármacos antirretrovirales en una población de personas afiliadas al régimen contributivo del Sistema General de Seguridad Social en Salud de Colombia, durante el 2015.  Materiales y métodos. Se hizo un estudio de corte transversal para analizar la formulación de fármacos antirretrovirales en pacientes tratados con estos entre el 1° de abril y el 30 septiembre del 2015. Se determinaron las variables sociodemográficas, farmacológicas y las comorbilidades, y el análisis estadístico se hizo mediante SPSS&#8482;, versión 23.0.  Resultados. Se hallaron 641 pacientes, la mayoría (60,2 %) hombres, con una edad media de 39,0±17 años. Los medicamentos más empleados fueron lamivudina-zidovudina (51,6 %), lopinavirritonavir (36 %) y efavirenz (24,5 %). La asociación lamivudina-zidovudina más lopinavir-ritonavir fue el esquema más prescrito (29,5 %), pero se encontraron 80 esquemas diferentes. El ser un adulto entre 45 y 64 años (odds ratio=2,25; IC95% 1,367-3,713; p=0,001) se asoció con una mayor probabilidad de recibir cuatro o más antirretrovirales. Del total de pacientes, 267 (41,6 %) recibían más de un medicamento simultáneamente (rango: 1-18 fármacos), especialmente fármacos contra las úlceras (57,3 %), hipolipemiantes (28,8 %) y antihipertensivos (28,5 %).  Conclusiones. Los pacientes en tratamiento antirretroviral están recibiendo medicamentos de elevado valor intrínseco en las dosis recomendadas, y presentan las mismas comorbilidades asociadas con las condiciones crónicas relacionadas con la edad. Además, reciben una gran variedad de esquemas que no se encuentran incluidos en las guías de práctica clínica.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Acquired immunodeficiency syndrome]]></kwd>
<kwd lng="en"><![CDATA[antiretroviral therapy, highly active]]></kwd>
<kwd lng="en"><![CDATA[drug prescriptions]]></kwd>
<kwd lng="en"><![CDATA[pharmacoepidemiology]]></kwd>
<kwd lng="es"><![CDATA[síndrome de inmunodeficiencia adquirida]]></kwd>
<kwd lng="es"><![CDATA[terapia antirretroviral altamente activa]]></kwd>
<kwd lng="es"><![CDATA[prescripciones de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[farmacoepidemiología]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kharsany]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Karim]]></surname>
<given-names><![CDATA[QA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV Infection and AIDS in Sub-Saharan Africa: Current status, challenges and opportunities]]></article-title>
<source><![CDATA[Open AIDS J]]></source>
<year>2016</year>
<volume>10</volume>
<page-range>34-48</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friedland]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Marking time in the Global HIV/AIDS pandemic]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2016</year>
<volume>316</volume>
<page-range>145-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fettig]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Swaminathan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Murrill]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global epidemiology of HIV]]></article-title>
<source><![CDATA[Clin North Am]]></source>
<year>2014</year>
<volume>28</volume>
<page-range>323-37</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabin]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Lundgren]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The natural history of HIV infection]]></article-title>
<source><![CDATA[Curr Opin HIV AIDS]]></source>
<year>2013</year>
<volume>8</volume>
<page-range>311-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hammer]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical practice. Management of newly diagnosed HIV infection]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2005</year>
<volume>353</volume>
<page-range>1702-10</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esté]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Cihlar]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current status and challenges of antiretroviral research and therapy]]></article-title>
<source><![CDATA[Antiviral Res]]></source>
<year>2010</year>
<volume>85</volume>
<page-range>25-33</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pau]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiretroviral therapy: Current drugs]]></article-title>
<source><![CDATA[Infect Dis Clin North Am]]></source>
<year>2014</year>
<volume>28</volume>
<page-range>371-402</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sawyer]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Hsiao]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single-tablet, once-daily treatment regimens for HIV]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>265-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Volberding]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Deeks]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiretroviral therapy and management of HIV infection]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>376</volume>
<page-range>49-62</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maartens]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Celum]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lewin]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV infection: Epidemiology, pathogenesis, treatment, and prevention]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>384</volume>
<page-range>258-71</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Alzate]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patrones de prescripción de antirretrovirales en 997 pacientes colombianos]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2008</year>
<volume>28</volume>
<page-range>78-86</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of antiretroviral treatment in Colombia]]></article-title>
<source><![CDATA[Rev Panam Salud Pública]]></source>
<year>2012</year>
<volume>32</volume>
<page-range>360-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Günthard]]></surname>
<given-names><![CDATA[HF]]></given-names>
</name>
<name>
<surname><![CDATA[Aberg]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Eron]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hoy]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Telenti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Benson]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International Antiviral Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2014</year>
<volume>312</volume>
<page-range>410-25</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Sax]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beginning antiretroviral therapy for patients with HIV]]></article-title>
<source><![CDATA[Infect Dis Clin North Am]]></source>
<year>2014</year>
<volume>28</volume>
<page-range>421-38</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Ripin]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Flexner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<collab>Conference on Antiretroviral Drug Optimization</collab>
<source><![CDATA[Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: A consensus statement]]></source>
<year>2012</year>
<volume>12</volume>
<page-range>550-60</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Werneck-Silva]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Prado]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dyspepsia in HIV-infected patients under highly active antiretroviral therapy]]></article-title>
<source><![CDATA[J Gastroenterol Hepatol]]></source>
<year>2007</year>
<volume>22</volume>
<page-range>1712-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dagenais-Lussier]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Mouna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Routy]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Tremblay]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sekaly]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[El-Far]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current topics in HIV-1 pathogenesis: The emergence of deregulated immunometabolism in HIV-infected subjects]]></article-title>
<source><![CDATA[Cytokine Growth Factor Rev]]></source>
<year>2015</year>
<volume>26</volume>
<page-range>603-13</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Giraldo]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Faus]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interacciones medicamentosas en pacientes infectados con el VIH: aproximación para establecer y evaluar su relevancia clínica]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2007</year>
<volume>31</volume>
<page-range>283-302</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Leyden]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Horberg]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[DeLorenze]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Quesenberry]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Older age and the response to and tolerability of antiretroviral therapy]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2007</year>
<volume>167</volume>
<page-range>684-91</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Fain]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Klotz]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The older HIV-positive adult: A critical review of the medical literature]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2008</year>
<volume>121</volume>
<page-range>1032-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luther]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkin]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV infection in older adults]]></article-title>
<source><![CDATA[Clin Geriatr Med]]></source>
<year>2007</year>
<volume>23</volume>
<page-range>567-83</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Santini-Oliveira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marins]]></surname>
<given-names><![CDATA[LMS]]></given-names>
</name>
<name>
<surname><![CDATA[Veloso]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Grinsztejn]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aging with HIV: A practical review]]></article-title>
<source><![CDATA[Braz J Infect Dis]]></source>
<year>2013</year>
<volume>17</volume>
<page-range>464-79</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cottrell]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Hadzic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kashuba]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical pharmacokinetic, pharmacodynamics and drug-interaction profile of the integrase inhibitor dolutegravir]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2013</year>
<volume>52</volume>
<page-range>981-94</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
